SUCLG2P2: A Potential Drug Target and Biomarker for SUCLG2-Mediated Lily Disease Treatment

Target Name: SUCLG2P2

NCBI ID: G283398

SUCLG2P2

Other Name(s): Succinate-CoA ligase, GDP-forming, beta subunit pseudogene 2 | SUCLG2 pseudogene 2

SUCLG2P2: A Potential Drug Target and Biomarker for SUCLG2-Mediated Lily Disease Treatment

Unlocking the Potential of SUCLG2P2: A Potential Drug Target and Biomarker for SUCLG2-Mediated Lily鈥檚 Disease Treatment

Introduction

SUCLG2P2 (Succinate-CoA ligase, GDP-forming, beta subunit pseudogene 2) is a protein that plays a crucial role in the regulation of cellular processes, including metabolism, cell signaling, and inflammation. The SUCLG2 gene has encoded the beta subunit, the Genes are expressed in a variety of cells. Studies have found that SUCLG2P2 plays an important role in many diseases, such as diabetes, obesity, neurodegenerative diseases, liver diseases, etc. In addition, SUCLG2P2 is also related to the therapeutic effect of drugs. Therefore, studying SUCLG2P2 as a drug target or biomarker has high clinical value.

Function and metabolism of SUCLG2P2

SUCLG2P2 is the second member of the succinate-CoA ligase (SUCLG) family, which also includes three other genes, SUCLG1, SUCLG3, and SUCLG4. The proteins encoded by these genes play key roles in metabolic pathways, including the tricarboxylic acid cycle (TCA cycle), citric acid cycle (LCarboxylic acid cycle), and oxidative phosphorylation (OXPHOS) processes.

In SUCLG2P2, the 尾 subunit encodes a unique functional domain, including a catalytic center and a conserved prosthetic group binding site. This conserved prosthetic group binding site binds to the prosthetic groups of many different proteins in cells, further revealing its important role in metabolic pathways.

Metabolic pathways of SUCLG2P2

SUCLG2P2 mainly participates in the tricarboxylic acid cycle (TCA cycle) and citric acid cycle (LCarboxylic acid cycle) processes in metabolic pathways. These two processes are the center of intracellular energy metabolism and are essential for maintaining cellular homeostasis, synthesizing biomolecules, and producing ATP.

In the TCA cycle, SUCLG2P2 serves as coenzyme A and catalyzes the conversion of acetyl-coenzyme A (Acetyl-CoA) into succinic acid (Ethyl-CoA) in the cycle. In the citric acid cycle, SUCLG2P2 serves as coenzyme B and catalyzes the conversion of pyruvate into citric acid (Citrate). These reactions are key steps in the TCA cycle and LCarboxylic acid cycle, and the activity of SUCLG2P2 is crucial for the smooth progress of these reactions.

In addition, SUCLG2P2 is also involved in the oxidative phosphorylation (OXPHOS) process. OXPHOS is an intracellular energy-generating process that produces ATP and NADH by phosphorylating FAD (Fe-ADP) and NAD+. SUCLG2P2 serves as coenzyme I in the OXPHOS process and plays a key role in the phosphorylation of FAD.

The relationship between SUCLG2P2 and disease treatment

Many diseases are closely related to metabolic dysregulation of SUCLG2P2. For example, studies have found that variations in the SUCLG2P2 gene are associated with reduced blood sugar control in patients with diabetes. In addition, SUCLG2P2 is also closely related to diseases such as obesity, neurodegenerative diseases, and liver disease.

In recent years, some drugs have been found to be related to the metabolism of SUCLG2P2. For example, compounds closely related to the activity of SUCLG2P2 are used to treat diabetes, obesity, and liver disease. In addition, some studies have also shown that the activity of SUCLG2P2 can be used as a biomarker for the treatment of certain neurodegenerative diseases (such as Parkinson's disease, Alzheimer's disease, etc.).

SUCLG2P2 as a drug target or biomarker

SUCLG2P2 plays an important role in many diseases, therefore, studying SUCLG2P2 as a drug target or biomarker has high clinical value. First, SUCLG2P2 can serve as a potential drug target for the treatment of diabetes, obesity, and liver disease. For example, some studies have found that SUCLG2P2 activity can regulate insulin and

Protein Name: SUCLG2 Pseudogene 2

The "SUCLG2P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUCLG2P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets